{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:24:41Z","timestamp":1787502281470,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejim.2024.10.016","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T08:14:07Z","timestamp":1730535247000},"page":"18-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["New strategies for the treatment of hyperkalemia"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-3686","authenticated-orcid":false,"given":"Stefano","family":"Masi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Dalpiaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Piludu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Piani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.10.016_bib0001","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000446268","article-title":"Potassium: from physiology to clinical implications","volume":"2","author":"Zacchia","year":"2016","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.ejim.2024.10.016_bib0002","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0016-5085(94)90184-8","article-title":"Pathophysiology of potassium absorption and secretion by the human intestine","volume":"107","author":"Agarwal","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2024.10.016_bib0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ckj\/sfu049","article-title":"Insulin for the treatment of hyperkalemia: a double-edged sword?","volume":"7","author":"Li","year":"2014","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ejim.2024.10.016_bib0004","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1093\/eurheartj\/suy028","article-title":"Hyperkalaemia: aetiology, epidemiology, and clinical significance","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.ejim.2024.10.016_bib0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJM198002213020803","article-title":"Adrenergic modulation of extrarenal potassium disposal","volume":"302","author":"Rosa","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.016_bib0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00424-008-0593-3","article-title":"Regulation of potassium (K) handling in the renal collecting duct","volume":"458","author":"Wang","year":"2009","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.ejim.2024.10.016_bib0007","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2024.10.016_bib0008","first-page":"F609","article-title":"Luminal influences on potassium secretion: low sodium concentration","volume":"246","author":"Good","year":"1984","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ejim.2024.10.016_bib0009","doi-asserted-by":"crossref","first-page":"20447","DOI":"10.1074\/jbc.R800083200","article-title":"ENaC at the cutting edge: regulation of epithelial sodium channels by proteases","volume":"284","author":"Kleyman","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejim.2024.10.016_bib0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/ki.1985.20","article-title":"Hormonal control of renal potassium excretion","volume":"27","author":"Field","year":"1985","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2024.10.016_bib0011","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/ckj\/sfab243","article-title":"How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies","volume":"15","author":"Humphrey","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ejim.2024.10.016_bib0012","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/jch.14633","article-title":"Prevalence and management of hyperkalemia in chronic kidney disease and heart failure patients in the Gulf Cooperation Council (GCC)","volume":"25","author":"AlSahow","year":"2023","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ejim.2024.10.016_bib0013","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1681\/ASN.2016121344","article-title":"How dangerous is hyperkalemia?","volume":"28","author":"Montford","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2024.10.016_bib0014","doi-asserted-by":"crossref","first-page":"e13941","DOI":"10.1111\/ijcp.13941","article-title":"Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions","volume":"75","author":"Tafesse","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejim.2024.10.016_bib0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008912","article-title":"Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes: a Danish population-based cohort study","volume":"7","author":"Thomsen","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2024.10.016_bib0016","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s12325-024-02835-8","article-title":"Hyperkalemia recurrence following medical nutrition therapy in patients with stage 3-4 chronic kidney disease: the REVOLUTIONIZE I real-world study","volume":"41","author":"Rowan","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejim.2024.10.016_bib0017","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2020.04.068","article-title":"Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: a blueprint for clinical trial design","volume":"313","author":"Savarese","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.10.016_bib0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mcna.2016.08.012","article-title":"Heart failure and hypertension: importance of prevention","volume":"101","author":"Pfeffer","year":"2017","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ejim.2024.10.016_bib0019","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2024.10.016_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005428","article-title":"Hyperkalemia after initiating renin-angiotensin system blockade: the stockholm creatinine measurements (SCREAM) project","volume":"6","author":"Bandak","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2024.10.016_bib0021","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ejim.2024.10.016_bib0022","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.10.016_bib0023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.kisu.2016.01.004","article-title":"Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena","volume":"6","author":"Epstein","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2024.10.016_bib0024","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.10.016_bib0025","first-page":"295","volume":"25","author":"Romano","year":"2018"},{"key":"10.1016\/j.ejim.2024.10.016_bib0026","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000369138","article-title":"Rim H. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease","volume":"128","author":"Gwoo","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ejim.2024.10.016_bib0027","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.016_bib0028","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.10.016_bib0029","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.016_bib0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized Aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.016_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002268","article-title":"Temporal trends and hospital variation in mineralocorticoid receptor antagonist use in veterans discharged with heart failure","volume":"4","author":"Dev","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2024.10.016_bib0032","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchf.2018.10.003","article-title":"Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.016_bib0033","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ehf2.12402","article-title":"Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK","volume":"6","author":"Linde","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.016_bib0034","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/ejhf.3214","article-title":"Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.016_bib0035","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.016_bib0036","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1074248416629549","article-title":"Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia","volume":"21","author":"Li","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ejim.2024.10.016_bib0037","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.10.016_bib0038","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ejhf.1860","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.016_bib0039","doi-asserted-by":"crossref","first-page":"425","DOI":"10.34067\/KID.0006782020","article-title":"Patiromer and spironolactone in resistant hypertension and advanced CKD: analysis of the randomized AMBER trial","volume":"2","author":"Agarwal","year":"2021","journal-title":"Kidney360."},{"key":"10.1016\/j.ejim.2024.10.016_bib0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/fca.11.71","article-title":"PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016","volume":"8","author":"Buysse","year":"2012","journal-title":"Future Cardiol"},{"key":"10.1016\/j.ejim.2024.10.016_bib0041","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.016_bib0042","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of Patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN Randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.10.016_bib0043","article-title":"Patiromer acetate induced hypercalcemia: an unreported adverse effect","volume":"2019","author":"Bhattarai","year":"2019","journal-title":"Case Rep Nephrol"},{"key":"10.1016\/j.ejim.2024.10.016_bib0044","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14740338.2018.1462335","article-title":"The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia","volume":"17","author":"Pitt","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ejim.2024.10.016_bib0045","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ehf2.14268","article-title":"Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure","volume":"10","author":"Tardif","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.016_bib0046","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.016_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2024.05.003","article-title":"Sodium zirconium Cyclosilicate in HFrEF and hyperkalemia: REALIZE-K design and baseline characteristics","author":"Kosiborod","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.016_bib0048","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.016_bib0049","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1002\/ejhf.1987","article-title":"Serum potassium in the PARADIGM-HF trial","volume":"22","author":"Ferreira","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.016_bib0050","first-page":"1460","article-title":"Sodium-Glucose Cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized","volume":"145","author":"Neuen","year":"2022","journal-title":"Controlled Trials. Circulation."},{"key":"10.1016\/j.ejim.2024.10.016_bib0051","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.016_bib0052","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: eMPEROR-reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.016_bib0053","first-page":"e13413","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists with ACEI\/ARB treatment for diabetic nephropathy: a meta-analysis","author":"Zuo","year":"2019","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejim.2024.10.016_bib0054","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ejim.2024.10.016_bib0055","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.016_bib0056","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2024.10.016_bib0057","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with finerenone in participants with stage 4 CKD and Type 2 diabetes: a FIDELITY Subgroup Analysis","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2024.10.016_bib0058","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.016_bib0059","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.016_bib0060","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.10.016_bib0061","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"Kidney Disease: improving global outcomes diabetes work G. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2024.10.016_bib0062","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"Kidney disease: improving global outcomes blood pressure work G. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2024.10.016_bib0063","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.016_bib0064","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/ejhf.2612","article-title":"An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum","volume":"24","author":"Burton","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.016_bib0065","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-024-07551-7","article-title":"Hyperkalaemia in Cardiological Patients: new Solutions for an old problem","author":"Abrignani","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ejim.2024.10.016_bib0066","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40620-019-00617-y","article-title":"Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian society of nephrology","volume":"32","author":"Bianchi","year":"2019","journal-title":"J Nephrol"},{"key":"10.1016\/j.ejim.2024.10.016_bib0067","first-page":"26","article-title":"Clinical practice guidelines: treatment of acute hyperkalaemia in adults","author":"Alfonzo","year":"2020","journal-title":"UK Renal Association"},{"key":"10.1016\/j.ejim.2024.10.016_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106277","article-title":"Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease","volume":"182","author":"Rossignol","year":"2022","journal-title":"Pharmacol Res"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524004345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524004345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T22:43:33Z","timestamp":1738536213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524004345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":68,"alternative-id":["S0953620524004345"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.10.016","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New strategies for the treatment of hyperkalemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}